Dorina Belotti

List of Publications by Year
in descending order

30 papers	1,626 citations	304743 22 h-index	477307 29 g-index
31 all docs	31 docs citations	31 times ranked	2334 citing authors

#	Article	IF	Citations
1	Apelin Resistance Contributes to Muscle Loss during Cancer Cachexia in Mice. Cancers, 2022, 14, 1814.	3.7	3
2	Alternative Vascularization Mechanisms in Tumor Resistance to Therapy. Cancers, 2021, 13, 1912.	3.7	28
3	Tumor vascular remodeling by thrombospondin-1 enhances drug delivery and antineoplastic activity. Matrix Biology, 2021, 103-104, 22-36.	3.6	2
4	CCN-Based Therapeutic Peptides Modify Pancreatic Ductal Adenocarcinoma Microenvironment and Decrease Tumor Growth in Combination with Chemotherapy. Cells, 2020, 9, 952.	4.1	23
5	The calcium-binding type III repeats domain of thrombospondin-2 binds to fibroblast growth factor 2 (FGF2). Angiogenesis, 2019, 22, 133-144.	7.2	37
6	Antimetastatic and antiangiogenic activity of trabectedin in cutaneous melanoma. Carcinogenesis, 2019, 40, 303-312.	2.8	28
7	Soluble stromaâ€related biomarkers of pancreaticÂcancer. EMBO Molecular Medicine, 2018, 10, .	6.9	56
8	Thrombospondin-1 promotes mesenchymal stromal cell functions via TGFÎ² and in cooperation with PDGF. Matrix Biology, 2016, 55, 106-116.	3.6	52
9	Antiangiogenic activity of trabectedin in myxoid liposarcoma: Involvement of host TIMPâ€1 and TIMPâ€2 and tumor thrombospondinâ€1. International Journal of Cancer, 2015, 136, 721-729.	5.1	50
10	Cediranib combined with chemotherapy reduces tumor dissemination and prolongs the survival of mice bearing patient-derived ovarian cancer xenografts with different responsiveness to cisplatin. Clinical and Experimental Metastasis, 2015, 32, 647-658.	3.3	17
11	Vascular Endothelial Growth Factor C Promotes Ovarian Carcinoma Progression through Paracrine and Autocrine Mechanisms. American Journal of Pathology, 2014, 184, 1050-1061.	3.8	56
12	Cisplatin plus paclitaxel and maintenance of bevacizumab on tumour progression, dissemination, and survival of ovarian carcinoma xenograft models. British Journal of Cancer, 2012, 107, 360-369.	6.4	29
13	Inhibition of SIRT2 Potentiates the Anti-motility Activity of Taxanes: Implications for Antineoplastic Combination Therapies. Neoplasia, 2012, 14, 846-IN16.	5.3	28
14	Targeting angiogenesis with compounds from the extracellular matrix. International Journal of Biochemistry and Cell Biology, 2011, 43, 1674-1685.	2.8	36
15	Identification of thrombin-like activity in ovarian cancer associated ascites and modulation of multiple cytokine networks. Thrombosis and Haemostasis, 2011, 106, 705-711.	3.4	18
16	Vascular Endothelial Growth Factor Stimulates Organ-Specific Host Matrix Metalloproteinase-9 Expression and Ovarian Cancer Invasion. Molecular Cancer Research, 2008, 6, 525-534.	3.4	65
17	Stereochemically pure Î±-trifluoromethyl-malic hydroxamates: synthesis and evaluation as inhibitors of matrix metalloproteinases. Tetrahedron, 2006, 62, 10171-10181.	1.9	7
18	Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy. Molecular Cancer Therapeutics, 2005, 4, 715-725.	4.1	27

#	Article	IF	Citations
19	Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin. Clinical Cancer Research, 2004, 10, 4813-4821.	7.0	144
20	Synthesis and evaluation of stereopure Î±-trifluoromethyl-malic hydroxamates as inhibitors of matrix metalloproteinases. Tetrahedron Letters, 2004, 45, 1611-1615.	1.4	47
21	Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. European Journal of Cancer, 2003, 39, 1948-1956.	2.8	87
22	Matrix metalloproteinases (MMP9 and MMP2) induce the release of vascular endothelial growth factor (VEGF) by ovarian carcinoma cells: implications for ascites formation. Cancer Research, 2003, 63, 5224-9.	0.9	241
23	HOXC5 and HOXC8 Expression Are Selectively Turned on in Human Cervical Cancer Cells Compared to Normal Keratinocytes. Biochemical and Biophysical Research Communications, 1999, 257, 738-745.	2.1	67
24	Expression of the 67 kD Laminin receptor in human ovarian carcinomas as defined by a monoclonal antibody, MLuC5. European Journal of Cancer, 1996, 32, 1598-1602.	2.8	39
25	TNP-470 (AGM-1470): Mechanisms of action and early clinical development. European Journal of Cancer, 1996, 32, 2520-2527.	2.8	108
26	Shedding of the 67-kD laminin receptor by human cancer cells. , 1996, 60, 226-234.		22
27	Prognostic significance of laminin production in relation with its receptor expression in human breast carcinomas. Breast Cancer Research and Treatment, 1995, 35, 195-199.	2.5	30
28	Inhibition of Angiogenesis and Murine Hemangioma Growth by Batimastat, a Synthetic Inhibitor of Matrix Metalloproteinases. Journal of the National Cancer Institute, 1995, 87, 293-298.	6.3	220
29	Enhancement of Metastatic Potential of Murine and Human Melanoma Cells by Laminin Receptor Peptide G: Attachment of Cancer Cells to Subendothelial Matrix as a Pathway for Hematogenous Metastasis. Journal of the National Cancer Institute, 1993, 85, 235-240.	6.3	44
30	Thrombospondin modulates basic fibroblast growth factor activities on endothelial cells. Exs, 1992, 61, 210-213.	1.4	15